Luvo Health Review

What Luvo Health charges

• Sermorelin: $199 — read from a pricing grid headed "4 WEEKS" whose rows print two figures each: "Sermorelin $199 $10 /week". ⛔ The header says four weeks and the unit label says per week, and the page contains no sentence reconciling them. Four weeks is thirteen charges a year, not twelve. What the second figure covers was not established and is not guessed here
• NAD+: $199 — from the same grid: "NAD+ Injection $199 $10 /week", under a header reading "4 WEEKS". Identical to this seller's growth-hormone figure to the dollar. The same grid prices its weight-loss and hormone lines the same way

A header and a unit label that contradict each other

The pricing page is a single grid covering every product the seller offers. Above it sits a period header reading four weeks. Beside each figure sits a unit label reading per week.

Those are not the same thing and the page contains no sentence reconciling them. Either the grid is priced per four-week cycle and the label is wrong, or it is priced per week and the header is wrong, and nothing on the page decides it.

What is certain either way is that four weeks is not a month. A four-week billing cycle produces thirteen charges a year rather than twelve, and any comparison table with a monthly column will understate the annual cost by roughly one payment.

Both peptide figures are recorded as ones that are not monthly rates for that reason alone, before the second-column question is even reached.

Two numbers per row, one unexplained

Every row carries a larger figure and then a small one attached to the per-week label. The small figure is identical across every product on the page, including products at wildly different prices.

A constant that does not vary with the product is almost certainly a fee of some kind rather than a price. This session did not establish what it is, and this review does not guess.

Guessing is the specific failure this site tries to avoid. A plausible reading written into a qualifier becomes a fact the next reader inherits, and there is no way to tell later that it was inferred.

The grid is therefore recorded exactly as printed, with the qualifier stating that the second figure was not established.

The catalogue is unusually wide and unusually flat

The grid names a broader set of compounds than most sellers on this roster: a growth-hormone peptide, a coenzyme, a tissue-repair peptide, a gonadotropin-releasing analogue, hormones, and both weight-loss injectables in standard and microdose forms.

Two rows carry no figure at all, printing only the constant. So the grid is not padded with unpriced items, but it is not complete either.

The two peptides this roster records carry the same figure to the dollar, which tells a reader nothing about the relative cost of the two compounds and something about how this seller prices.

Putting every product on one page with a figure on nearly every line is genuinely useful, and it is the reason this seller is worth reading despite the period problem.

Entity clear, everything else absent

The terms name the operating company in their heading and again in their opening sentence, in both capitalisations. There is no ambiguity and no vendor's name standing in for it.

Screened by that entity and by the brand against the regulator's warning-letter index, nothing returns.

No dispensing pharmacy is named, no certificate of analysis exists on the pages read, and no state coverage list is published.

The nonsense-path control on this host returned a small, clean not-found page, so the pages that returned content are pages that exist.

How we verified this

• Loaded the pricing page and the terms with a full browser user-agent, printing the effective URL beside the requested one on both.
• Ran a nonsense-path control on the host in the same run, which returned a clean not-found status with a small body.
• Joined the page's text nodes before matching any figure — necessary here because the grid renders each cell separately and a per-node read would have split every row.
• Recorded the grid header and the per-figure unit label as printed, and recorded that the page contains no sentence reconciling them.
• Recorded both peptide figures as ones that are not monthly rates, on the four-week header alone.
• Noted that the second figure is constant across every row including rows at very different prices, and declined to state what it is.
• Read the terms' heading and opening sentence for the operating company.
• Screened the operating company and the brand against the regulator's warning-letter index, with a nonsense query as a control in the same run.